DB
HQL

Dmitry Balyasny’s abrdn Life Sciences Investors HQL Stock Holding History

Dmitry Balyasny’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,340
Closed -$284K – 3291
2025
Q3 		$284K Buy
+18,340
New +$251K ﹤0.01% 2595

Other funds holding HQL

SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Dmitry Balyasny's HQL Position: Q4 2025 in Review

Dmitry Balyasny sold out of abrdn Life Sciences Investors (HQL) in Q4 2025, closing a stake of 18,340 shares — an estimated $284K sold.

Dmitry Balyasny first reported a position in HQL in Q3 2025 and held it in 1 quarter. The position peaked at $284K in Q3 2025. 73 funds tracked by Wall St. Rank hold HQL as of Q4 2025.

  • Dmitry Balyasny reported no remaining abrdn Life Sciences Investors position as of Q4 2025 after selling out during the quarter.
  • Dmitry Balyasny sold 18,340 abrdn Life Sciences Investors shares in Q4 2025, an estimated $284K.
  • Dmitry Balyasny first reported a position in abrdn Life Sciences Investors in Q3 2025 and held it in 1 quarter.
  • Dmitry Balyasny's abrdn Life Sciences Investors position peaked at $284K in Q3 2025.
  • 73 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.